Ido Y, Kilo C, Williamson J R
Department of Pathology, Washington University School of Medicine, St Louis, MO 63110, USA.
Nephrol Dial Transplant. 1996;11 Suppl 5:72-5. doi: 10.1093/ndt/11.supp5.72.
Many lines of evidence attest to a multifactorial pathogenesis of diabetic complications in humans and in animal models of diabetes. Increased sorbitol pathway metabolism and non-enzymatic glycation products have been implicated by many investigators in the pathogenesis of vascular and neural dysfunction as well as early vascular structural changes in animal models of diabetes. The present studies were undertaken to assess the mechanisms that mediate vascular dysfunction associated with these biochemical imbalances.
Three different animal models of diabetes were used: (1) rats with diabetes induced by injection of streptozotocin; (2) non-diabetic rats with acute hyperglycaemia of 5 h duration induced by i.v. glucose infusion at a rate sufficient to produce plasma glucose levels comparable to those in diabetic rats; and (3) the skin chamber granulation tissue model in which vessels in the chamber are exposed to buffer containing 5 or 30 mM glucose +/- pharmacological agents or 0.1 microM glycated rat serum albumin +/- pharmacological agents. Vascular function was assessed by injection of 11.3 microns 46Sc microspheres for quantification of blood flow and by injection of [125I] and [131I]bovine serum albumin for quantification of vascular albumin permeation.
Vascular dysfunction induced by elevated glucose levels (increased blood flow and increased albumin permeation) in all three models was prevented by inhibitors of sorbitol pathway metabolism, inhibitors of nitric oxide synthesis and inhibitors of prostaglandin synthesis. In the skin chamber model vascular dysfunction induced by elevated glucose levels and by glycated rat serum albumin was prevented by superoxide dismutase, probucol and inhibitors of nitric oxide synthase.
These observations suggest that vascular dysfunction induced by increased sorbitol pathway metabolism (caused by elevated glucose levels) and by products of non-enzymatic glycation (at normal glucose levels) is mediated by a common final pathway consistent with a scenario in which: increases superoxide production-->increases intracellular calcium levels-->increases nitric oxide synthesis-->increases blood flow and increases vascular permeability.
多项证据证明人类糖尿病并发症及糖尿病动物模型具有多因素发病机制。许多研究者认为,山梨醇途径代谢增加及非酶糖基化产物与糖尿病动物模型的血管和神经功能障碍以及早期血管结构改变的发病机制有关。本研究旨在评估介导与这些生化失衡相关的血管功能障碍的机制。
使用三种不同的糖尿病动物模型:(1)注射链脲佐菌素诱导糖尿病的大鼠;(2)通过静脉输注葡萄糖诱导持续5小时急性高血糖的非糖尿病大鼠,输注速率足以使血浆葡萄糖水平与糖尿病大鼠相当;(3)皮肤腔室肉芽组织模型,其中腔室内的血管暴露于含有5或30 mM葡萄糖±药理剂或0.1 μM糖化大鼠血清白蛋白±药理剂的缓冲液中。通过注射11.3微米46Sc微球定量血流,并通过注射[125I]和[131I]牛血清白蛋白定量血管白蛋白渗透来评估血管功能。
在所有三种模型中,山梨醇途径代谢抑制剂、一氧化氮合成抑制剂和前列腺素合成抑制剂可预防高血糖水平诱导的血管功能障碍(血流增加和白蛋白渗透增加)。在皮肤腔室模型中,超氧化物歧化酶、普罗布考和一氧化氮合酶抑制剂可预防高血糖水平和糖化大鼠血清白蛋白诱导的血管功能障碍。
这些观察结果表明,山梨醇途径代谢增加(由高血糖水平引起)和非酶糖基化产物(在正常血糖水平下)诱导的血管功能障碍是由一条共同的最终途径介导的,该途径符合以下情况:超氧化物生成增加→细胞内钙水平增加→一氧化氮合成增加→血流增加和血管通透性增加。